Online inquiry

IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8736MR)

This product GTTS-WQ8736MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCR5 gene. The antibody can be applied in AIDS, Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000579.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1234
UniProt ID P51681
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8736MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14182MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ9566MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ7243MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ9037MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ14890MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ12179MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ9264MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ2083MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AIN457
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW